



FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Date:- February 12, 2025

To,

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001.

BSE Script Code: 531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

NSE Symbol: FDC

Sub: Press Release on Q3 - FY 2024-25 Results.

Dear Sir/Ma'am,

Please find attached herewith the Press Release issued in relation to the Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter and nine months ended December 31, 2024.

Kindly take the same on record.

Thanking you,

Yours truly

For FDC Limited

Varsharani Katre

Company Secretary & Compliance Officer

M No.: FCS-8948




FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

FDC Limited reports Q3FY25 results

Mumbai, 12th Feb 2025: FDC Limited (NSE: FDC, BSE: 531599, ISIN: INE258B01022) reported financials for the second quarter ended 31st Dec 2024.



Consolidated Q3FY25 FDC and 9MFY25 reported

Rs. in crores	Q3FY25	Q3FY24	YoY Grw %	9MFY25	9MFY24	YoY Grw %
Operating Revenue	464	458	1.3%	1,616	1,481	9.1%
EBITDA	47	84	-44.3%	269	282	-4.7%
EBITDA %	10.1%	18.3%		16.6%	19.1%	
PBT	51	98	-47.5%	304	331	-8.2%
PAT	37	79	-53.2%	228	259	-11.8%
EPS (Rs.)	2.28	4.86	-53.2%	14.02	15.89	-11.8%

Commenting on the results;

The company delivered revenue growth of 9.1% in 9MFY25, driven by robust performance across all business segments, except for US Formulations. The export formulations business witnessed a 20.7% YoY decline in 9MFY25, primarily due to lower sales in the US market. On the other hand, the API business demonstrated strong momentum, recording a 25.6% YoY growth in Q3FY25 and 25.1% YoY growth in 9MFY25.

EBITDA for Q3FY25 and 9MFY25 was impacted by lower sales in export formulation business, price reduction in the Electral range of products, driven by NLEM price revisions changes in the product mix, and higher employee costs.

CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176





FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

Business-wise Sales Performance

₹ Cr	Q3FY25	YoY Grw %	9MFY25	YoY Grw %2
Net Sales	464	1.3%	1,616	9.1%
India Formulations	388	6.9%	1,358	13.7%
US Formulations	8	-75.7%	54	-52.1%
Emerging Markets	39	2.5%	119	12.8%
API Sales	28	25.6%	82	25.1%

India Market:

The sale of branded formulations in India for Q3FY25 was Rs. 388 crores, with a growth of 6.9% on YoY and lower by 8.1% over QoQ. For the first nine months, sales were at Rs. 1,358 crores, a healthy growth of 13.7% over the same period last year. Overall sales in the Indian market accounted for 82% of total consolidated sales for the quarter and 84% for 9MFY25.

As per secondary sales data by IQVIA for the quarter ended Dec 31, 2024, the Company delivered YoY growth of 8.6% compared to the Indian Pharmaceutical Market (IPM) growth of 7.4% YoY. Electral has moved up to 20th in IPM in MAT Dec'24 as compared to 23rd in the same period last year.

Further, the company was the 5th fastest growing company as per MAT Dec'24 among the Top 25 companies.

Export Formulations Market:

Formulation Sales in the Export market were Rs. 47 crores in Q3FY25, down by 34.2% over YoY and lower by 23.2% over QoQ. For the first nine sales were Rs. 172 crores, down by 20.7% over the same period last year. Export formulation business impacted during the period primarily due to lower sales in USA markets.

During the quarter, the Company secured approval for one ANDA for Cefixime Tablets USP 400mg

API Business:

API business showed good traction of growth momentum with sales of Rs. 28 crores in Q3FY25, up by 25.6% over YoY and lower by 4.3% over QoQ and accounted for 6% of total consolidated sales. During 9MFY25, the API business grew by 25%, registering sales of Rs. 82crs.

CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176





FDC Limited

MANUFACTURERS & EXPORTERS OF FOODS, DRUGS & CHEMICALS

ABOUT FDC LTD

FDC was established in the year 1936 as a partnership firm. This firm was incorporated as a Company in 1940, with the vision of building a world-class company while contributing to making the nation self-reliant in healthcare. To cite a few, FDC carries forward the flaming spirit of its first dream, achieving accreditations from the US-FDA, UK-MHRA, MCC-RSA, and the UAE. FDC is a forerunner in the manufacturing and marketing of Oral Rehydration Salts (ORS), anti-infectives and ophthalmic. FDC has also set up globally approved, multi-location manufacturing facilities for Active Pharmaceuticals Ingredients (APIs) as well as Finished Dosage Forms. These facilities are located at Roha, Waluj and Sinnar in Maharashtra, Verna in Goa and Baddi in Himachal Pradesh. FDC markets more than 300 products in India and exports many of these to over 50 countries. FDC strives to explore, innovate and integrate solutions with modern technology, empowering talent and expanding healthcare horizons for a better quality of life for millions globally.

Disclaimer

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve several risks and uncertainties including the impact of Covid-19 and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.



CORPORATE OFFICE : 142-48, S. V. Road, Jogeshwari (W), Mumbai - 400 102. INDIA
Tel.: +91-22-6291 7900 / 950 / 2678 0652 / 2653 / 2656 • Fax : +91-22-2677 3462
E-mail : fdc@fdcindia.com • Website : www.fdcindia.com

REGISTERED OFFICE : B-8, M.I.D.C. Industrial Area, Waluj - 431 136, Dist. Aurangabad. INDIA
Tel.: 0240-255 4407 / 255 4299 / 255 4967 • Fax : 0240-255 4299
E-mail : waluj@fdcindia.com • CIN : L24239MH1940PLC003176